Fate Therapeutics: Q1 Earnings Snapshot
Fate Therapeutics Inc. (FATE) on Wednesday reported a loss of $18.9 million in its first quarter. On a per-share basis, the San Diego-based company said it had a loss of 19 cents. The results beat Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was for a loss of 55 cents per share
SAN DIEGO (AP) — SAN DIEGO (AP) — Fate Therapeutics Inc. (FATE) on Wednesday reported a loss of $18.9 million in its first quarter.
On a per-share basis, the San Diego-based company said it had a loss of 19 cents.
The results beat Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was for a loss of 55 cents per share.
The clinical-stage biotech company that develops stem cell treatments posted revenue of $59 million in the period, also surpassing Street forecasts. Eight analysts surveyed by Zacks expected $42.2 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a FATE">Zacks stock report on FATE at https://www.zacks.com/ap/FATE
